tetano
Editor, Senior Moderator
Virol J
. 2023 Aug 21;20(1):187.
doi: 10.1186/s12985-023-02158-0. Immunological profile of mice immunized with a polyvalent virosome-based influenza vaccine
Francisco Noé Fonseca[SUP] 1 [/SUP], Vanessa Haach[SUP] 2 [/SUP], Franciana Volpato Bellaver[SUP] 3 [/SUP], Gabrielly Bombassaro[SUP] 3 [/SUP], Danielle Gava[SUP] 1 [/SUP], Luciano Paulino da Silva[SUP] 4 [/SUP], Lana Flavia Baron[SUP] 2 [/SUP], Mayara Simonelly[SUP] 5 [/SUP], Wanessa Araújo Carvalho[SUP] 6 [/SUP], Rejane Schaefer[SUP] 1 [/SUP], Ana Paula Bastos[SUP] 7 [/SUP]
Affiliations
Background: Influenza A virus (IAV) causes respiratory disease in pigs and is a major concern for public health. Vaccination of pigs is the most successful measure to mitigate the impact of the disease in the herds. Influenza-based virosome is an effective immunomodulating carrier that replicates the natural antigen presentation pathway and has tolerability profile due to their purity and biocompatibility.
Methods: This study aimed to develop a polyvalent virosome influenza vaccine containing the hemagglutinin and neuraminidase proteins derived from the swine IAVs (swIAVs) H1N1, H1N2 and H3N2 subtypes, and to investigate its effectiveness in mice as a potential vaccine for swine. Mice were immunized with two vaccine doses (1 and 15 days), intramuscularly and intranasally. At 21 days and eight months later after the second vaccine dose, mice were euthanized. The humoral and cellular immune responses in mice vaccinated intranasally or intramuscularly with a polyvalent influenza virosomal vaccine were investigated.
Results: Only intramuscular vaccination induced high hemagglutination inhibition (HI) titers. Seroconversion and seroprotection (> 4-fold rise in HI antibody titers, reaching a titer of ≥ 1:40) were achieved in 80% of mice (intramuscularly vaccinated group) at 21 days after booster immunization. Virus-neutralizing antibody titers against IAV were detected at 8 months after vaccination, indicating long-lasting immunity. Overall, mice immunized with the virosome displayed greater ability for B, effector-T and memory-T cells from the spleen to respond to H1N1, H1N2 and H3N2 antigens.
Conclusions: All findings showed an efficient immune response against IAVs in mice vaccinated with a polyvalent virosome-based influenza vaccine.
Keywords: Influenza a virus; Nanovaccine; Seroprotection; Vaccination; Vaccine.
. 2023 Aug 21;20(1):187.
doi: 10.1186/s12985-023-02158-0. Immunological profile of mice immunized with a polyvalent virosome-based influenza vaccine
Francisco Noé Fonseca[SUP] 1 [/SUP], Vanessa Haach[SUP] 2 [/SUP], Franciana Volpato Bellaver[SUP] 3 [/SUP], Gabrielly Bombassaro[SUP] 3 [/SUP], Danielle Gava[SUP] 1 [/SUP], Luciano Paulino da Silva[SUP] 4 [/SUP], Lana Flavia Baron[SUP] 2 [/SUP], Mayara Simonelly[SUP] 5 [/SUP], Wanessa Araújo Carvalho[SUP] 6 [/SUP], Rejane Schaefer[SUP] 1 [/SUP], Ana Paula Bastos[SUP] 7 [/SUP]
Affiliations
- PMID: 37605141
- DOI: 10.1186/s12985-023-02158-0
Background: Influenza A virus (IAV) causes respiratory disease in pigs and is a major concern for public health. Vaccination of pigs is the most successful measure to mitigate the impact of the disease in the herds. Influenza-based virosome is an effective immunomodulating carrier that replicates the natural antigen presentation pathway and has tolerability profile due to their purity and biocompatibility.
Methods: This study aimed to develop a polyvalent virosome influenza vaccine containing the hemagglutinin and neuraminidase proteins derived from the swine IAVs (swIAVs) H1N1, H1N2 and H3N2 subtypes, and to investigate its effectiveness in mice as a potential vaccine for swine. Mice were immunized with two vaccine doses (1 and 15 days), intramuscularly and intranasally. At 21 days and eight months later after the second vaccine dose, mice were euthanized. The humoral and cellular immune responses in mice vaccinated intranasally or intramuscularly with a polyvalent influenza virosomal vaccine were investigated.
Results: Only intramuscular vaccination induced high hemagglutination inhibition (HI) titers. Seroconversion and seroprotection (> 4-fold rise in HI antibody titers, reaching a titer of ≥ 1:40) were achieved in 80% of mice (intramuscularly vaccinated group) at 21 days after booster immunization. Virus-neutralizing antibody titers against IAV were detected at 8 months after vaccination, indicating long-lasting immunity. Overall, mice immunized with the virosome displayed greater ability for B, effector-T and memory-T cells from the spleen to respond to H1N1, H1N2 and H3N2 antigens.
Conclusions: All findings showed an efficient immune response against IAVs in mice vaccinated with a polyvalent virosome-based influenza vaccine.
Keywords: Influenza a virus; Nanovaccine; Seroprotection; Vaccination; Vaccine.